Coronary Artery Disease (CAD), Obstructive Sleep Apnea (OSA)
Conditions
Keywords
Coronary artery disease, Chemoreceptors, Sympathetic nerve activity, Exercise
Brief summary
The investigators hypothesize that chemoreflex response of muscle sympathetic nerve activity (MSNA) during hypoxia and hypercapnia will be increased in coronary artery disease (CAD) patients and that the presence of obstructive sleep apnea (OSA) will potentiate these responses. And, that the exercise training would decrease the chemoreflex response of MSNA in these patients.
Detailed description
Forty patients with coronary artery disease, with (n=20) and without (n=20) obstructive sleep apnea will be studied. A healthy control, age-paired group (n=10) will be also evaluated. The patients will be submitted to a polysomnography and randomized for clinical follow-up or exercise training for four months. It will evaluated the autonomic function, chemoreflex control of sympathetic activity during hypoxic and hypercapnic maneuvers, endothelial function and inflammatory markers.
Interventions
OTHERAerobic exercise training
The patients will be submitted to four months of aerobic exercise training, three time a week.
Sponsors
University of Sao Paulo General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
35 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Diagnosis of stable coronary artery disease; Age between 35-60 years, male and female; BMI \<30 kg/m2 Not involved in a regular exercise program at least three months before the survey;
Exclusion criteria
* Patients with angina and / or ischemia, * Patients with diabetic neuropathy and / or ischemia of the lower limbs; * Previous diagnosis of chronic pulmonary, neurological and orthopedic diseases, neoplasia, renal failure and insulin-dependent diabetes mellitus; * Patients with acute myocardial infarction, cardiac surgery or hospitalization of cardiac origin six months before the study and carriers of pacemaker / implantable defibrillator; * Patients with cardiac dysfunction (ejection fraction of left ventricle \<40%); * Current smoking and pregnant women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Chemoreflex control of MSNA at rest and during exercise. | baseline and after 4 months | Chemoreflex control of MSNA will be measured by microneurography technique during the gas mixture known exposure at rest and during exercise |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life | baseline and after 4 months | Quality of life will be measured by the questionnaire Short-Form Health Survey (SF-36). |
| Inflammatory markers | baseline and after 4 months | Inflammatory markers will be measured by markers present in blood samples. |
| Neurovascular Control | baseline and after 4 months | Neurovascular Control will be measured by venous occlusion plethysmography technique during the exposure mixture of gases known at rest and during exercise. |
| Endothelial Function | baseline and after 4 months | Endothelial Function will be measured by markers present in blood samples. |
| Symptoms of Depression | baseline and after 4 months | The level of symptoms of depression will be measured by the Beck scale. |
| Mood State | baseline and after 4 months | Mood State will be measured by the profile of mood states (POMS) scale. |
| Anxiety Trait and State | baseline and after 4 months | Anxiety Trait and State will be measured by the Spielberger state trait anxiety inventory (STAI). |
Countries
Brazil
Contacts
Primary ContactMaria Urbana PB Rondon, PhD
Backup ContactCarlos Alcino do Nascimento Filho, BS
Outcome results
None listed